Aligos Therapeutics (ALGS) Stock Forecast, Price Target & Predictions
ALGS Stock Forecast
Aligos Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a -84.84% downside from ALGS’s last price of $19.79) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.
ALGS Price Target
The average price target for Aligos Therapeutics (ALGS) is $3.00 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential -84.84% downside from ALGS's last price of $19.79.
ALGS Analyst Ratings
According to 13 Wall Street analysts, Aligos Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for ALGS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (30.77%), 8 'Hold' (61.54%), 1 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).
Aligos Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 06, 2023 | - | Piper Sandler | $3.00 | $1.22 | 146.91% | -84.84% |
| Jan 06, 2023 | - | Jefferies | $3.00 | $0.99 | 203.03% | -84.84% |
The latest Aligos Therapeutics stock forecast, released on Jan 06, 2023 by Piper Sandler company, set a price target of $3.00, which represents a 146.91% increase from the stock price at the time of the forecast ($1.22), and a -84.84% decrease from ALGS last price ($19.79).
Aligos Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $19.79 | $19.79 | $19.79 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Aligos Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aligos Therapeutics's last price of $19.79. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 19, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Jul 19, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jan 06, 2023 | Barclays | - | Equal-Weight | Downgrade |
| Jan 06, 2023 | Wedbush | - | Neutral | Downgrade |
| Jan 06, 2023 | Raymond James | - | Outperform | Downgrade |
| Jan 06, 2023 | J.P. Morgan | - | Neutral | Downgrade |
| Jan 06, 2023 | Piper Sandler | Overweight | Neutral | Downgrade |
Aligos Therapeutics's last stock rating was published by H.C. Wainwright on Sep 20, 2024. The company gave ALGS a "Buy" rating, the same as its previous rate.
Aligos Therapeutics Financial Forecast
Aligos Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $3.54M | $4.11M | $2.57M | $910.00K |
| Avg Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $433.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $2.18M | $1.07M |
| High Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $433.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $2.62M | $1.29M |
| Low Forecast | $333.33K | $333.33K | $333.33K | $333.33K | $433.33K | $333.33K | $1.06M | $1.60M | $2.50M | $2.15M | $750.00K | $1.75M | $857.42K |
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.65% | 5.47% | 1.18% | 0.85% |
Aligos Therapeutics's average Quarter revenue forecast for Sep 23 based on 1 analysts is $2.50M, with a low forecast of $2.50M, and a high forecast of $2.50M. ALGS's average Quarter revenue forecast represents a -29.32% decrease compared to the company's last Quarter revenue of $3.54M (Dec 22).
Aligos Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $-19.07M | $-22.68M | $-18.04M | $-34.57M | $-26.76M |
| Avg Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-86.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-150.00K | $-29.30M | $-31.51M |
| High Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-86.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-150.00K | $-23.44M | $-25.21M |
| Low Forecast | $-66.67K | $-66.67K | $-66.67K | $-66.67K | $-86.67K | $-66.67K | $-212.20K | $-320.00K | $-500.00K | $-430.00K | $-150.00K | $-35.15M | $-37.82M |
| Surprise % | - | - | - | - | - | - | - | - | 38.14% | 52.75% | 120.28% | 1.18% | 0.85% |
undefined analysts predict ALGS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aligos Therapeutics's previous annual EBITDA (undefined) of $NaN.
Aligos Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $-18.04M | $-21.89M | $-18.62M | $-35.62M | $-27.67M |
| Avg Forecast | $-19.44M | $-19.21M | $-18.65M | $-17.33M | $-15.66M | $-13.53M | $-25.06M | $-43.91M | $-74.48M | $-78.40M | $-90.86M | $-30.25M | $-32.59M |
| High Forecast | $-19.44M | $-19.21M | $-18.65M | $-11.62M | $-11.46M | $-13.53M | $-25.06M | $-17.89M | $-74.48M | $-78.40M | $-90.86M | $-24.20M | $-26.08M |
| Low Forecast | $-19.44M | $-19.21M | $-18.65M | $-26.50M | $-22.99M | $-13.53M | $-25.06M | $-69.92M | $-74.48M | $-78.40M | $-90.86M | $-36.30M | $-39.11M |
| Surprise % | - | - | - | - | - | - | - | - | 0.24% | 0.28% | 0.20% | 1.18% | 0.85% |
Aligos Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALGS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Aligos Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $6.44M | $7.12M | $5.26M | $6.45M | $5.78M |
| Avg Forecast | $827.66K | $827.66K | $827.66K | $827.66K | $1.08M | $827.66K | $2.58M | $3.97M | $6.21M | $5.34M | $1.83M | $5.32M | $2.61M |
| High Forecast | $827.66K | $827.66K | $827.66K | $827.66K | $1.08M | $827.66K | $2.58M | $3.97M | $6.21M | $5.34M | $1.83M | $6.38M | $3.13M |
| Low Forecast | $827.66K | $827.66K | $827.66K | $827.66K | $1.08M | $827.66K | $2.58M | $3.97M | $6.21M | $5.34M | $1.83M | $4.25M | $2.09M |
| Surprise % | - | - | - | - | - | - | - | - | 1.04% | 1.33% | 2.88% | 1.21% | 2.22% |
Aligos Therapeutics's average Quarter SG&A projection for Dec 23 is $3.97M, based on 1 Wall Street analysts, with a range of $3.97M to $3.97M. The forecast indicates a -38.34% fall compared to ALGS last annual SG&A of $6.44M (Sep 23).
Aligos Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | $-0.41 | $-0.51 | $-0.44 | $-0.84 | $-0.74 |
| Avg Forecast | $-3.10 | $-3.06 | $-2.97 | $-2.76 | $-2.50 | $-2.16 | $-4.00 | $-7.00 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
| High Forecast | $-3.10 | $-3.06 | $-2.97 | $-1.85 | $-1.83 | $-2.16 | $-4.00 | $-2.85 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
| Low Forecast | $-3.10 | $-3.06 | $-2.97 | $-4.23 | $-3.67 | $-2.16 | $-4.00 | $-11.15 | $-11.88 | $-12.50 | $-14.50 | $-18.19 | $-22.50 |
| Surprise % | - | - | - | - | - | - | - | - | 0.03% | 0.04% | 0.03% | 0.05% | 0.03% |
According to undefined Wall Street analysts, Aligos Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALGS previous annual EPS of $NaN (undefined).
Aligos Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.19 | $10.00 | 740.34% | Buy |
| CTMX | CytomX Therapeutics | $0.87 | $5.73 | 558.62% | Buy |
| TIL | Instil Bio | $24.76 | $78.25 | 216.03% | Hold |
| NUVB | Nuvation Bio | $2.70 | $6.75 | 150.00% | Buy |
| ASMB | Assembly Biosciences | $14.72 | $35.50 | 141.17% | Buy |
| NXTC | NextCure | $1.29 | $3.00 | 132.56% | Buy |
| ACHL | Achilles Therapeutics | $1.07 | $2.00 | 86.92% | Buy |
| ALGS | Aligos Therapeutics | $19.79 | $3.00 | -84.84% | Hold |